ESSA Pharma Inc.
EPIX · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $136 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $16 | $24 | $23 | $68 |
| Gross Profit | -$16 | -$24 | -$23 | $68 |
| % Margin | – | – | – | 50% |
| R&D Expenses | -$531 | $3,484 | $5,474 | $4,188 |
| G&A Expenses | $5,528 | $3,863 | $4,443 | $3,751 |
| SG&A Expenses | $5,528 | $3,873 | $4,443 | $3,751 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | -$256 | -$244 |
| Operating Expenses | $4,996 | $7,358 | $9,661 | $7,695 |
| Operating Income | -$4,996 | -$7,382 | -$9,685 | -$7,695 |
| % Margin | – | – | – | -5,668% |
| Other Income/Exp. Net | $993 | $1,007 | $1,153 | $1,339 |
| Pre-Tax Income | -$4,003 | -$6,375 | -$8,532 | -$6,355 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,003 | -$6,375 | -$8,532 | -$6,355 |
| % Margin | – | – | – | -4,681.4% |
| EPS | -0.09 | -0.14 | -0.19 | -0.14 |
| % Growth | 35.6% | 26.3% | -35.7% | – |
| EPS Diluted | -0.09 | -0.14 | -0.19 | -0.14 |
| Weighted Avg Shares Out | 44,389 | 44,389 | 44,366 | 44,366 |
| Weighted Avg Shares Out Dil | 44,389 | 44,389 | 44,366 | 44,366 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,032 | $1,009 | $1,147 | $1,338 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $16 | $24 | $1,409 | $23 |
| EBITDA | -$4,980 | -$6,351 | -$8,509 | -$6,332 |
| % Margin | – | – | – | -4,664.6% |